Edition:
United Kingdom

Integra Lifesciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

63.67USD
9:00pm BST
Change (% chg)

$0.38 (+0.60%)
Prev Close
$63.29
Open
$63.20
Day's High
$63.80
Day's Low
$62.89
Volume
94,303
Avg. Vol
258,740
52-wk High
$67.43
52-wk Low
$43.04

Latest Key Developments (Source: Significant Developments)

Integra Lifesciences Reports Q2 GAAP EPS Of $0.14
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Integra LifeSciences Holdings Corp ::INTEGRA LIFESCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.60.Q2 GAAP EARNINGS PER SHARE $0.14.Q2 REVENUE $366.2 MILLION VERSUS I/B/E/S VIEW $368.2 MILLION.Q2 EARNINGS PER SHARE VIEW $0.60 -- THOMSON REUTERS I/B/E/S.SAYS USING FOREIGN CURRENCY RATES IN EFFECT AT APRIL GUIDANCE, Q2 REVENUE WOULD HAVE BEEN $368.4 MILLION .SEES FY 2018 ADJUSTED EARNINGS PER SHARE $2.36 TO $2.42.SEES FY 2018 GAAP EARNINGS PER SHARE $0.71 TO $0.77.SAYS EXITS FIRST WAVE OF CODMAN TRANSITION SERVICES AGREEMENTS.SAYS REITERATING FY 2018 ORGANIC SALES GROWTH GUIDANCE OF ABOUT 5%.SEES FY2018 TOTAL REVENUE OF $1.475 BILLION TO $1.490 BILLION.FY2018 EARNINGS PER SHARE VIEW $2.40, REVENUE VIEW $1.49 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Integra Lifesciences Prices Public Offering Of Common Stock
Thursday, 10 May 2018 

May 9 (Reuters) - Integra LifeSciences Holdings Corp ::INTEGRA LIFESCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.25 MILLION COMMON SHARES PRICED AT $58.50PER SHARE.  Full Article

Integra Lifesciences Announces Amendment And Extension Of Credit Facility
Monday, 7 May 2018 

May 7 (Reuters) - Integra LifeSciences Holdings Corp ::INTEGRA LIFESCIENCES ANNOUNCES AMENDMENT AND EXTENSION OF CREDIT FACILITY.INTEGRA LIFESCIENCES - NEW TERMS INCLUDE DECREASE IN APPLICABLE INTEREST RATES, COMMITMENT FEES, EXTENDS MATURITY OF CREDIT FACILITY TO MAY 3, 2023.INTEGRA LIFESCIENCES HOLDINGS CORP - OVERALL SIZE OF CREDIT FACILITY REMAINS AT $2.2 BILLION.  Full Article

Integra Lifesciences Reports Q1 Adjusted Earnings Per Share $0.58
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Integra LifeSciences Holdings Corp ::INTEGRA LIFESCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.58.Q1 GAAP EARNINGS PER SHARE $0.14.Q1 REVENUE $357.1 MILLION VERSUS I/B/E/S VIEW $349.1 MILLION.Q1 EARNINGS PER SHARE VIEW $0.49 -- THOMSON REUTERS I/B/E/S.INTEGRA LIFESCIENCES HOLDINGS SAYS RAISING ITS FULL-YEAR 2018 GAAP EARNINGS PER SHARE GUIDANCE RANGE BY $0.08 TO A NEW RANGE OF $0.69 TO $0.77.INTEGRA LIFESCIENCES HOLDINGS SAYS RAISING FULL-YEAR 2018 ADJUSTED EARNINGS PER SHARE TO $2.34 TO $2.42.INTEGRA LIFESCIENCES HOLDINGS SAYS COMPANY IS REITERATING ITS FULL-YEAR 2018 GUIDANCE FOR ORGANIC SALES TO BE APPROXIMATELY 5.0%.COMPANY IS RAISING ITS FULL-YEAR 2018 REVENUE GUIDANCE BY $10 MILLION TO A NEW RANGE OF $1.47 BILLION TO $1.49 BILLION.  Full Article

Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%​.- ‍IS STILL EVALUATING IMPACT OF TAX CUTS AND JOBS ACT OF 2017 ON ITS GAAP FINANCIAL RESULTS​.INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY FOURTH QUARTER 2017 FINANCIAL RESULTS.SEES Q4 2017 REVENUE ABOUT $365 MILLION.Q4 EARNINGS PER SHARE VIEW $0.55, REVENUE VIEW $351.0 MILLION -- THOMSON REUTERS I/B/E/S.INTEGRA LIFESCIENCES-Q4 2017 ADJUSTED EPS, EXCLUDING IMPACT FROM TAX CUTS,JOBS ACT OF 2017,TO EXCEED HIGH-END OF PREVIOUS GUIDANCE RANGE OF $0.53 TO $0.57.  Full Article

Integra Lifesciences Holdings Corp ‍Reaffirms 2017 Financial Guidance As Provided On Oct 26, 2017​
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍REAFFIRMING 2017 FINANCIAL GUIDANCE AS PROVIDED ON OCTOBER 26, 2017​.- ‍REAFFIRMING 2018 ADJUSTED EARNINGS PER SHARE IN RANGE OF $2.25 TO $2.35​.INTEGRA LIFESCIENCES SAYS PROVIDING 2018 PRELIMINARY REVENUE ESTIMATE IN RANGE OF $1.46 BILLION TO $1.48 BILLION - SEC FILING.INTEGRA LIFESCIENCES - ESTABLISHING FIVE-YEAR FINANCIAL TARGETS OF ABOUT $2 BILLION IN REVENUE AND AN ADJUSTED EBITDA MARGIN RANGE OF 28% TO 30%.FY2018 EARNINGS PER SHARE VIEW $2.30 -- THOMSON REUTERS I/B/E/S.FY2017 EARNINGS PER SHARE VIEW $1.85, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Integra Lifesciences Holdings Corp ::CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING.  Full Article

Integra Lifesciences Q3 adjusted earnings per share $0.45
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Integra Lifesciences Holdings Corp ::Integra Lifesciences reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.45.Q3 GAAP earnings per share $0.04.Q3 revenue $279 million versus I/B/E/S view $286.1 million.Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.83 to $1.87.Sees FY 2017 gaap earnings per share $0.24 to $0.30.Sees FY 2017 revenue $1.165 billion to $1.175 billion.Integra Lifesciences Holdings Corp - "‍we expect some storm-related disruptions to continue to impact revenues in Q4"​.Integra Lifesciences Holdings Corp - ‍full-year 2017 organic revenue growth is now expected to be about 4 pct​.FY2017 earnings per share view $1.91, revenue view $1.15 billion -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences says Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal
Wednesday, 15 Feb 2017 

Integra Lifesciences Holdings Corp : Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal after conditions to closing are satisfied .Depuy Synthes to pay termination fee of $41.8 million if co terminates deal due to Depuy Synthes’S breach of exclusivity obligations.  Full Article

Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson for $1.045 bln
Wednesday, 15 Feb 2017 

Integra Lifesciences Holdings Corp : Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash . Deal for $1.045 billion in cash . Transaction expected to be accretive to integra's adjusted earnings per diluted share by at least $0.22 in first fy . Says expects codman neurosurgery revenue to experience some initial disruption in first year of combination . Says expects codman neurosurgery revenue to grow 3% to 6% longer term . Says has obtained committed financing, subject to customary closing conditions, from BofA Merrill Lynch and JPMorgan .Deal expected to also accelerate path to achieving co's aspirational targets of $2 billion in revenue, 30% adjusted ebitda margin.  Full Article